Sequestration Boosting Interest In Specialty Drug Cost Control – Express Scripts’ Paz
This article was originally published in The Pink Sheet Daily
Express Scripts CEO George Paz noted that federal budget cuts under sequestration are being layered on top of already tight budgets for payers in both the government and private sector, driving greater interest in the PBM’s cost-savings programs for high-cost specialty products.
You may also be interested in...
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
The tactic aims to allow the new Biden administration to scrutinize so-called “midnight rules” issued in the final days of the Trump administration before they take effect. One reg targeted by the freeze is the recent SUNSET rule from the US HHS, which would require the department and its agencies – including the FDA – to review all regulations every 10 years to determine whether they’re still necessary.
Use of preferred and non-preferred specialty formulary tiers will be allowed but preferred tiers are not necessarily limited to generics and biosimilars and coinsurance for non-preferred specialty drugs cannot exceed 33%.